Pharmacoeconomic evaluation of herd immunity conferred by seven-valent pneumococcal conjugate vaccine (Prevnar®) in canada based on calgary region epidemiological data

被引：0
|
作者：
Casciano, R.
Doyle, J.
Kellner, J. D.
Dolgitser, M.
Stern, L.
Krukas, M. R.
Fontaine, L.
Vicente, C.
机构：
[1] Analyt Int, New York, NY USA
[2] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada
[3] Wyeth Pharmaceut, Markham, ON, Canada
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)69039-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A164 / A165
页数：2
相关论文
共 10 条
  • [1] Pharmacoeconomic evaluation of herd protection for the seven-valent pneumococcal conjugate vaccine in Switzerland
    Ciuryla, VT
    Siegartel, LR
    Casciano, R
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 761 - 761
  • [2] A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain
    Asensi, F
    De Jose, M
    Lorente, M
    Moraga, F
    Ciuryla, V
    Arikian, S
    Casciano, R
    Vento, M
    [J]. VALUE IN HEALTH, 2004, 7 (01) : 36 - 51
  • [3] A multinational pharmacoeconomic evaluation of direct and indirect immunity conferred by the seven-valent pneumococcal conjugate vaccine (PCV7)
    Strutton, D. R.
    Casciano, R.
    Stern, L.
    Doyle, J.
    Berenson, K.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A442 - A442
  • [4] Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada
    Ricketson, Leah J.
    Conradi, Nicholas G.
    Vanderkooi, Otto G.
    Kellner, James D.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (01) : 22 - 27
  • [5] A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada
    Lebel, MH
    Kellner, JD
    Ford-Jones, EL
    Hvidsten, K
    Wang, ECY
    Ciuryla, V
    Arikian, S
    Casciano, R
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (03) : 259 - 268
  • [6] Eradication of Invasive Pneumoccal Disease due to the Seven-valent Pneumococcal Conjugate Vaccine Serotypes in Calgary, Alberta
    Leal, Jenine
    Vanderkooi, Otto G.
    Church, Deirdre L.
    MacDonald, Judy
    Tyrrell, Gregory J.
    Kellner, James D.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (09) : E169 - E175
  • [7] Incorporating of herd immunity into pharmacoeconomic evaluation of pneumococcal conjugate vaccine PNC-7
    Claes, C
    Reinert, RR
    Schulenburg, JM
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 298 - 298
  • [8] Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
    Miller, Elizabeth
    Andrews, Nicholas J.
    Waight, Pauline A.
    Slack, Mary P. E.
    George, Robert C.
    [J]. LANCET INFECTIOUS DISEASES, 2011, 11 (10): : 760 - 768
  • [9] Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine
    Suga, Shigeru
    Chang, Bin
    Asada, Kazutoyo
    Akeda, Hideki
    Nishi, Junichiro
    Okada, Kenji
    Wakiguchi, Hiroshi
    Maeda, Akihiko
    Oda, Megumi
    Ishiwada, Naruhiko
    Saitoh, Akihiko
    Oishi, Tomohiro
    Hosoya, Mitsuaki
    Togashi, Takehiro
    Oishi, Kazunori
    Ihara, Toshiaki
    [J]. VACCINE, 2015, 33 (45) : 6054 - 6060
  • [10] Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar®) administered in previously unvaccinated Spanish children aged 24 to 36 months
    Fernández, JD
    Arregui, BC
    Carril, AZ
    Esteban, VA
    Ruiz, JA
    Jausoro, ED
    San Pedro, IM
    Michelena, JL
    Carballo, CM
    Sánchez, MIQ
    Therón, IA
    Cimino, CO
    Fletcher, MA
    Domínguez, AP
    [J]. VACCINE, 2005, 23 (16) : 1917 - 1922
1